Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects

被引:42
|
作者
Choe, Young Gil [1 ]
Jin, Wook [2 ]
Cho, Yong Kyun [1 ]
Chung, Won Gil [1 ]
Kim, Hong Joo [1 ]
Jeon, Woo Kyu [1 ]
Kim, Byung Ik [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Kangbuk Samsung Hosp, Seoul 110746, South Korea
[2] Gacheon Univ Med & Sci, Lab Mol Dis & Cell Regulat, Lee Gil Ya Canc & Diabet Inst, Inchon, South Korea
关键词
ApoB; AI ratio; apolipoprotein; non-alcoholic fatty liver disease; CORONARY-HEART-DISEASE; MIDDLE-AGED MEN; METABOLIC SYNDROME; A-I; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; HEPATIC STEATOSIS; ARTERY-DISEASE; RISK; STEATOHEPATITIS;
D O I
10.1111/jgh.12077
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims The apolipoprotein B/AI (ApoB/AI) ratio is a strong new risk factor for cardiovascular (CV) disease. Although recent reports have shown the effects of non-alcoholic fatty liver disease (NAFLD) on CV disease, NAFLD is under-recognized as a predictable risk factor for CV disease. This study was performed to assess the independent association between ApoB/AI ratio and NAFLD. Methods This cross-sectional study was performed in 9162 subjects who participated in a health checkup program in South Korea in 2009. The presence of NAFLD was defined by ultrasonographic examination. Logistic regression analysis was applied to estimate the association between ApoB/AI ratio and NAFLD. The odds ratio (OR) and P were estimated according to the categorized level of the ApoB/AI ratio. Results The overall prevalence of NAFLD was 27.9% (n=2554, 41.7% of the men, 10.8% of the women). Men had a 5.91-fold (95% CI 5.286.62) greater risk for NAFLD than women. After adjusting for confounding factors, the ApoB/AI ratio was more closely associated with the prevalence of NAFLD than with any other lipid profiles (OR 8.537 in men, 16.6 in women). NAFLD risk increased as the quartiles of the ApoB/AI ratio increased from the first to the fourth quartile (OR 1.359, 2.173 and 3.124, P for trend<0.001). Conclusion The ApoB/AI ratio was associated with the prevalence of NAFLD in nondiabetic subjects and was independent of obesity and other metabolic components. This result suggests that NAFLD may provide additional information for atherosclerosis progression and CV risks.
引用
收藏
页码:678 / 683
页数:6
相关论文
共 50 条
  • [11] Non-alcoholic fatty liver disease and cardiovascular risk
    Brea, Angel
    Puzo, Jose
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (04) : 1109 - 1117
  • [12] Current treatment of non-alcoholic fatty liver disease
    Ahmed, Mohamed H.
    Byrne, Christopher D.
    DIABETES OBESITY & METABOLISM, 2009, 11 (03) : 188 - 195
  • [13] Non-alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance
    Fiorentino, Teresa Vanessa
    Succurro, Elena
    Sciacqua, Angela
    Andreozzi, Francesco
    Perticone, Francesco
    Sesti, Giorgio
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2020, 36 (08)
  • [14] Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Stavropoulos, Konstantinos
    Imprialos, Konstantinos
    Pittaras, Andreas
    Faselis, Charles
    Narayan, Puneet
    Kokkinos, Peter
    CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (03) : 239 - 245
  • [15] A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD
    Younossi, Zobair M.
    Stepanova, Maria
    Henry, Linda
    Racila, Andrei
    Lam, Brian
    Pham, Huong T.
    Hunt, Sharon
    LIVER INTERNATIONAL, 2017, 37 (08) : 1209 - 1218
  • [16] Paediatric non-alcoholic fatty liver disease
    Nobili, Valerio
    Pinzani, Massimo
    GUT, 2010, 59 (05) : 561 - 564
  • [17] Non-alcoholic fatty liver disease and lipotoxicity
    Wasilewska, Natalia
    Lebensztejn, Dariusz Marek
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2021, 7 (01) : 1 - 6
  • [18] Non-alcoholic Fatty Liver Disease in Children
    Muzurovic, Emir
    Polyzos, Stergios A.
    Mikhailidis, Dimitri P.
    Borozan, Sanja
    Novosel, Dusanka
    Cmiljanic, Oleg
    Kadic, Natasa
    Mantzoros, Christos S.
    CURRENT VASCULAR PHARMACOLOGY, 2023, 21 (01) : 4 - 25
  • [19] Lipidomics in non-alcoholic fatty liver disease
    Kartsoli, Sofia
    Kostara, Christina E.
    Tsimihodimos, Vasilis
    Bairaktari, Eleni T.
    Christodoulou, Dimitrios K.
    WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (08) : 436 - 450
  • [20] Extrahepatic complications of non-alcoholic fatty liver disease: Its impact beyond the liver
    Velarde-Ruiz Velasco, J. A.
    Garcia-Jimenez, E. S.
    Garcia-Zermeno, K. R.
    Morel-Cerda, E. C.
    Aldana-Ledesma, J. M.
    Castro-Narro, G. E.
    Cerpa-Cruz, S.
    Tapia-Calderon, D. K.
    Mercado-Jauregui, L. A.
    Contreras-Omana, R.
    REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2019, 84 (04): : 472 - 481